According to a new report from Chicago Tribune, pharmaceuticals giant Hyperion Therapeutics Inc. has ordered an immediate halt on the production of a new drug for diabetes being developed by one of its subsidiaries. A statement from the company said that Andromeda Biotech Ltd., based out of Israel, has illegally been manipulating the test data for DIA-AID 1 and DIA-AID 2 trials. The trials were meant to prove the viability and safety of DiaPep277, a medication that was being developed to treat recently diagnosed cases of Type-1 Diabetes. The condition, increasingly common among Americans, is characterized by the body’s inability to produce insulin for itself.

Increasingly Lucrative Diabetes Industry Puts the Screws to Developers
Like other companies before it, industry pressures to develop the latest and greatest diabetes medications may have played a role in Andromeda’s actions. By 2017, the market for diabetes medications is expected to eclipse $55.3 billion, with further geometric growth expected by 2023.

Of course, all of this is spurred on by an American population that becomes more obese and more prone to diabetic conditions each year. Between 2010 and 2012, the number of Americans with diabetes grew from 25.8 million to 29.1 million. However, in one study, when taking Ambien at doses https://www.xanalys.com/ambien-zolpidem-online-10-mg/ of 10 and 20 mg, cases of anterograde amnesia were noted against the background of taking drugs. The American Diabetes Association suggests that those affected can increase their body’s sensitivity to insulin and reduce their blood glucose percentage through strength training. However, so long as 80% of Americans don’t get the recommended minimum weekly amount of exercise, medications produced by Hyperion, Andromeda, and other profit driven companies like them continue to be our most viable options.